Marijo B. Kambere

FDA investigator · also recorded as Ae Marijo B. Kambere

Appears on 11 documents from 2015 to 2021, mostly at sites in China. Most often cites written procedures; deviations (21 CFR 211.100).

11
Documents on file
2.7
Observations per 483
2015
First seen
2021
Most recent

What they cite most

From 30 observations

Activity by year

2015: 1, 2016: 1, 2017: 1, 2018: 4, 2019: 3, 2021: 1

Where

China 7 · Arizona 2 · Washington 2

Is Marijo B. Kambere coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

11 documents, newest first
FirmOpen
483 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Jan 14, 2021 · Lianyungang, China
483 Tianjin Asymchem Pharmaceuticals Co., Ltd.Dec 6, 2019 · Tianjin, China
483 Ningxia Qiyuan Pharmaceutical Co., Ltd.Jun 28, 2019 · Yinchuan, China
483 Xinyu Pharmaceutical Co., Ltd.Mar 15, 2019 · SuZhou County, China
483 Dongying Tiandong Pharmaeutical Co., LtdOct 19, 2018 · Dongying, China
483 Dongying Tiandong Pharmaeutical Co., Ltd.Oct 19, 2018 · Dongying, China
483 Avella of Deer Valley dba Avella Specialty PharmacyApr 25, 2018 · Phoenix, Arizona

About this profile

What does Marijo B. Kambere inspect?

Marijo B. Kambere appears on 11 documents on file covering 9 sites, mostly in China.

What do they cite most often?

21 CFR 211.100 (written procedures; deviations), followed by 21 CFR 211.22 and 21 CFR 211.113.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Marijo B. Kambere is dated Jan 14, 2021.